mk-2214

MK-2214

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">mk-2214</th>
</tr>
<tr>
<td class="label">Epitope</td>
<td>Location</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>Microtubule binding</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau231</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau413</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target Epitope</td>
</tr>
<tr>
<td class="label">MK-2214</td>
<td>p-tau413</td>
</tr>
<tr>
<td class="label">Eilanetug (E2814)</td>
<td>MTBR (HVPGG)</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>aa 235-250</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>N-terminus</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>p-tau217</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Conformational</td>
</tr>
</table>

Overview

MK-2214

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">mk-2214</th>
</tr>
<tr>
<td class="label">Epitope</td>
<td>Location</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>Microtubule binding</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau231</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau413</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target Epitope</td>
</tr>
<tr>
<td class="label">MK-2214</td>
<td>p-tau413</td>
</tr>
<tr>
<td class="label">Eilanetug (E2814)</td>
<td>MTBR (HVPGG)</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>aa 235-250</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>N-terminus</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>p-tau217</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Conformational</td>
</tr>
</table>

Overview

MK-2214 is an investigational monoclonal antibody therapeutic developed by Merck & Co. (known as MSD outside the United States and Canada) that specifically targets tau protein phosphorylated at threonine 413 (p-tau413). This represents a unique approach in the tau immunotherapy field, focusing on a specific phosphorylation site that has emerged as a promising biomarker for Alzheimer's disease pathology and a potential therapeutic target["@tau2024"][@merck2024].

Scientific Rationale

Tau Phosphorylation in Alzheimer's Disease

The tau protein undergoes extensive post-translational modifications in Alzheimer's disease, with over 40 phosphorylation sites identified[@yoshiyama2013]. Among these, certain phosphorylation sites have emerged as particularly disease-relevant:

Key Phospho-Tau Epitopes:

• p-tau181: First discovered AD biomarker, elevated in CSF
• p-tau217: Highest diagnostic accuracy for AD, correlates with amyloid
• p-tau231: Earliest detectable change, useful for early detection
• p-tau413: Associated with advanced pathology, unique targeting opportunity

Why Target p-tau413?

The choice of p-tau413 as a therapeutic target offers several advantages[@tau2024][@ahmad2022]:

Biological significance of Thr413:

• Located in the N-terminal region of tau (outside microtubule-binding domain)
• Phosphorylation at this site is rare in normal brain
• Associated with pathological tau aggregation
• Detectable in CSF as a biomarker of disease progression

Comparison with Other Phospho-Tau Targets

Mechanism of Action

Antibody Properties

MK-2214 is designed to selectively bind and neutralize tau species phosphorylated at threonine 413[@tau2024]:

Epitope Specificity:

• High affinity for p-tau413
• Minimal cross-reactivity with non-phosphorylated tau
• Preference for aggregated over monomeric p-tau413

Brain Penetration Considerations

Like all anti-tau antibodies, MK-2214 faces the challenge of crossing the blood-brain barrier[@butchart2019]:

BBB Challenges:

• Typical brain:plasma ratios of 0.1-1% for conventional IgG
• FcRn-mediated transcytosis provides limited brain exposure
• Higher dosing may partially overcome this limitation

• Optimized antibody engineering for brain penetration
• Dose selection based on preclinical and Phase I data
• Monitoring of CSF and plasma biomarkers

Clinical Development

Preclinical Development

The development of MK-2214 required extensive preclinical validation:

Antibody Selection Criteria:

• High affinity for p-tau413 with minimal off-target binding
• IgG1 isotype for optimal Fc-mediated effector functions
• Humanized framework to minimize immunogenicity
• Brain penetration properties optimized for CNS target

• Transgenic mouse models (P301S, rTg4510) with tau pathology
• In vitro binding studies using human AD brain tissue
• Pharmacodynamic studies showing reduction of p-tau413 species
• Safety pharmacology studies supporting advancement to human trials

Phase I Status

MK-2214 is currently in Phase I clinical development[@merck2024]:

Development Timeline:

• First-in-human studies initiated (estimated 2023-2024)
• Early-phase trials evaluating safety, tolerability, PK/PD
• Ongoing as of 2024

• Assess safety and tolerability in healthy volunteers and AD patients
• Determine pharmacokinetic properties
• Evaluate target engagement biomarkers
• Establish optimal dosing for future trials

Clinical Trial Design Considerations

Anti-tau antibody trials face unique challenges[@bittlinger2021][@cummings2024]:

Patient Selection:

• Early AD (MCI due to AD or mild dementia)
• Confirmed tau pathology (via PET or CSF biomarkers)
• Amyloid-positive status (for combination with anti-amyloid)

• Cognitive measures: CDR-SB, iADRS, ADAS-Cog
• Biomarker endpoints: tau PET, CSF p-tau413
• Safety: ARIA monitoring (less relevant than anti-amyloid)

Comparison with Other Anti-Tau Antibodies

The anti-tau immunotherapy field has multiple programs targeting different epitopes[@bittlinger2021][@cummings2024]:

Unique Features of MK-2214

Merck's Tau Pipeline Strategy

Broader Portfolio

Merck has been developing multiple approaches to Alzheimer's disease beyond MK-2214[@merck2024]:

Related Programs:

• Anti-amyloid antibodies
• BACE inhibitors (discontinued)
• Tau-targeted approaches
• Neuroprotective agents

• Focus on biomarker-guided patient selection
• Emphasis on early disease stages
• Combination therapy approach

Comparison with Industry Trends

The tau immunotherapy field has faced significant challenges[@cummings2024]:

Field-Wide Issues:

• Multiple high-profile failures (gosuranemab, semorinemab, tilavonemab, zagotenemab)
• Brain penetration limitations
• Late-stage patient enrollment
• Biomarker-clinical disconnect

• More disease-specific targeting
• Earlier biomarker changes
• May address propagating species

Biomarker Context

p-tau413 as a Biomarker

While primarily a therapeutic target, p-tau413 also serves as a biomarker[@blennow2022][@palmqvist2020]:

CSF Biomarker Properties:

• Elevated in AD vs. controls
• Correlates with tau PET burden
• Tracks disease progression
• Potentially responds to therapy

• Correlates with p-tau181 and p-tau217
• More specific for AD than total tau
• Complements amyloid and neurodegeneration markers

Monitoring Target Engagement

For anti-tau therapeutics, biomarker monitoring is critical[@zetterberg2019]:

Expected Biomarker Changes:

• Plasma p-tau413: May increase (antibody-bound release)
• CSF p-tau413: May decrease (reduced pathology)
• Tau PET: May slow accumulation

• Complex biomarker dynamics
• Limited validation for p-tau413
• Need for standardized assays

Therapeutic Implications

Potential Patient Population

MK-2214 would be indicated for:

Combination Therapy Potential

Given the complexity of AD pathology, combination approaches are likely[@cummings2024]:

Rationale for Combination:

• Anti-amyloid + anti-tau may provide synergistic effects
• Addresses multiple pathological domains
• May improve clinical outcomes

• Increased complexity of trial design
• Safety monitoring for multiple agents
• Regulatory pathway for combinations

Current Status and Future Directions

Development Timeline

As of 2024, MK-2214 remains in Phase I development[@merck2024]:

Near-term Milestones:

• Completion of Phase I studies
• Decision on Phase II/III advancement
• Publication of Phase I data

• Dependent on Phase I results
• May require 3-5 years for potential approval
• Competitive with other anti-tau programs

Challenges and Opportunities

Challenges:

• Demonstrating clear efficacy in a crowded field
• Achieving adequate brain penetration
• Selecting appropriate patient population
• Competing with anti-amyloid therapies

• p-tau413 targeting is unique in the field
• Merck's resources and experience
• Growing understanding of tau biology

Company Information

Developer: Merck & Co., Inc. (MSD outside US and Canada)

Headquarters: Rahway, New Jersey, USA

Key Facts:

• Founded in 1891
• One of the largest pharmaceutical companies globally
• Strong neuroscience pipeline including Alzheimer's disease programs

• Developed verubecestat (BACE inhibitor, discontinued)
• Multiple biomarker programs in AD
• Extensive clinical trial infrastructure

Cross-Links

• [Tau Protein](/proteins/tau)
• [Phosphorylated Tau Biomarkers](/biomarkers/p-tau-181)
• [Anti-Tau Immunotherapies](/therapeutics/anti-tau-immunotherapies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau PET Imaging](/diagnostics/tau-pet)
• [Merck](/companies/merck)

See Also

• [Tau Pathology](/mechanisms/tau-pathology)
• [Tau Hyperphosphorylation](/mechanisms/tau-hyperphosphorylation)
• [Anti-Tau Antibody Programs](/therapeutics/anti-tau-immunotherapy-programs)
• [Tau Aggregation Inhibitors](/therapeutics/anti-tau-aggregation-therapy)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving mk-2214 discovered through SciDEX knowledge graph analysis: